Regulus Therapeutics (RGLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -30,037 | -21,976 | -14,152 | -7,139 | -28,323 |
| Depreciation Amortization | 70 | 44 | 39 | -8 | -63 |
| Accounts payable and accrued liabilities | 29 | 424 | 188 | 406 | -110 |
| Other Working Capital | 257 | -589 | -1,126 | -1,408 | 550 |
| Other Operating Activity | 2,913 | 1,454 | 685 | 35 | 2,420 |
| Operating Cash Flow | $-26,768 | $-20,643 | $-14,366 | $-8,114 | $-25,526 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 15,101 | 10,101 | 15,000 | 15,000 | -14,759 |
| PPE Investments | -610 | -542 | -1 | -1 | -361 |
| Investing Cash Flow | $14,491 | $9,559 | $14,999 | $14,999 | $-15,120 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -3,304 | -2,478 | -1,652 | -826 | N/A |
| Common Stock Issued | 15,120 | 15,167 | 14,054 | 21 | 4,491 |
| Financing Cash Flow | $11,816 | $12,689 | $12,402 | $-805 | $4,491 |
| Beginning Cash Position | 24,290 | 24,290 | 24,290 | 24,290 | 60,445 |
| End Cash Position | 23,829 | 25,895 | 37,325 | 30,370 | 24,290 |
| Net Cash Flow | $-461 | $1,605 | $13,035 | $6,080 | $-36,155 |
| Free Cash Flow | |||||
| Operating Cash Flow | -26,768 | -20,643 | -14,366 | -8,114 | -25,526 |
| Capital Expenditure | -613 | -542 | -1 | -1 | -361 |
| Free Cash Flow | -27,381 | -21,185 | -14,367 | -8,115 | -25,887 |